ACS Publications. Most Trusted. Most Cited. Most Read
My Activity

Mechanism-Based Inactivation of Cytochrome P450 3A4 by L-754,394

View Author Information
Department of Medicinal Chemistry, University of Washington, Box 357610, Seattle, Washington 98195, Department of Chemistry, Room 477 Fulmer Hall, Washington State University, Pullman, Washington 99164-4630, Biomedical Research Centre, Ninewells Hospital and Medical School, Dundee, UK, and Department of Drug Metabolism, WP-26A-2044, Merck Research Laboratories, West Point, Pennsylvania 19486
Cite this: Biochemistry 2000, 39, 15, 4276–4287
Publication Date (Web):March 16, 2000
Copyright © 2000 American Chemical Society

    Article Views





    Read OnlinePDF (305 KB)


    Mechanism-based inactivation of human liver P450 3A4 by L-754,394, a Merck compound synthesized as a potential HIV protease inhibitor, was investigated using recombinant P450 3A4. Enzyme inactivation was characterized by a small partition ratio (3.4 or 4.3 ± 0.4), i.e., the total number of metabolic events undergone by the inhibitor divided by the number of enzyme inactivating events, lack of reversibility upon extensive dialysis, no decrease in the characteristic 450-nm species relative to control, and covalent modification of the apoprotein. The major and minor products formed during the inactivation of P450 3A4 were the monohydroxylated and the dihydrodiol metabolites of L-754,394, respectively. L-754,394 that had been adducted to P450 3A4 was hydrolyzed under the conditions used for SDS-PAGE, Ni2+ affinity chromatography, and proteolytic digestion. In addition, the modification was not stable to the acidic conditions of HPLC separation and CNBr digestion. The labile nature of the peptide adduct and the nonstoichiometric binding of the inactivating species to P450 3A4 precluded the direct identification of a covalently modified amino acid residue or the peptide to which it was attached. However, Tricine SDS-PAGE in combination with MALDI-TOF-MS and homology modeling, allowed I257-M317 to be tentatively identified as an active site peptide, while prior knowledge of the stability of N-, O-, and S-linked conjugates of activated furans implicates Glu307 as the active site amino acid that is labeled by L-754, 394.

     This work was supported by NIH Grant GM32165 (Bethesda, MD) and the Dorothy Danforth-Compton Graduate Student Fellowship (L.K.L.).

     Department of Medicinal Chemistry, University of Washington.


     Present Address:  School of Pharmacy, Rm. S-926, Department of Pharmaceutical Chemistry, University of CA, San Francisco, San Francisco, CA 94143-0446.

     Department of Chemistry, Washington State University.

     Biomedical Research Centre.


     To whom correspondence should be addressed:  Department of Medicinal Chemistry, University of Washington, Box 357610, Seattle, Washington 98195. Telephone:  (206) 543-9481. Fax:  (206) 685-3252. E-mail:  [email protected].

     Merck Research Laboratories.

    Cited By

    This article is cited by 38 publications.

    1. M. Saeed Mirzaei, Maxim V. Ivanov, Avat Arman Taherpour, Saber Mirzaei. Mechanism-Based Inactivation of Cytochrome P450 Enzymes: Computational Insights. Chemical Research in Toxicology 2021, 34 (4) , 959-987.
    2. Nikhil Taxak, Sourav Kalra, and Prasad V. Bharatam . Mechanism-Based Inactivation of Cytochromes by Furan Epoxide: Unraveling the Molecular Mechanism. Inorganic Chemistry 2013, 52 (23) , 13496-13508.
    3. Lisa A. Peterson . Reactive Metabolites in the Biotransformation of Molecules Containing a Furan Ring. Chemical Research in Toxicology 2013, 26 (1) , 6-25.
    4. Suvi T. M. Orr, Sharon L. Ripp, T. Eric Ballard, Jaclyn L. Henderson, Dennis O. Scott, R. Scott Obach, Hao Sun, and Amit S. Kalgutkar . Mechanism-Based Inactivation (MBI) of Cytochrome P450 Enzymes: Structure–Activity Relationships and Discovery Strategies To Mitigate Drug–Drug Interaction Risks. Journal of Medicinal Chemistry 2012, 55 (11) , 4896-4933.
    5. Manuel Tzouros and Axel Pähler. A Targeted Proteomics Approach to the Identification of Peptides Modified by Reactive Metabolites. Chemical Research in Toxicology 2009, 22 (5) , 853-862.
    6. Hao Sun and Garold S. Yost. Metabolic Activation of a Novel 3-Substituted Indole-Containing TNF-α Inhibitor: Dehydrogenation and Inactivation of CYP3A4. Chemical Research in Toxicology 2008, 21 (2) , 374-385.
    7. Hideo Yukinaga, Tomonori Takami, Sho-hei Shioyama, Zenzaburo Tozuka, Hiroshi Masumoto, Osamu Okazaki and Ken-ichi Sudo. Identification of Cytochrome P450 3A4 Modification Site with Reactive Metabolite Using Linear Ion Trap-Fourier Transform Mass Spectrometry. Chemical Research in Toxicology 2007, 20 (10) , 1373-1378.
    8. Bo Wen,, Catalin E. Doneanu,, Carlos A. Gartner,, Arthur G. Roberts,, William M. Atkins, and, Sidney D. Nelson. Fluorescent Photoaffinity Labeling of Cytochrome P450 3A4 by Lapachenole:  Identification of Modification Sites by Mass Spectrometry. Biochemistry 2005, 44 (6) , 1833-1845.
    9. Bernard Meunier,, Samuël P. de Visser, and, Sason Shaik. Mechanism of Oxidation Reactions Catalyzed by Cytochrome P450 Enzymes. Chemical Reviews 2004, 104 (9) , 3947-3980.
    10. DAN A. ROCK, LARRY C. WIENKERS. Characterization of Cytochrome P450 Mechanism Based Inhibition. 2022, 465-526.
    11. Jaydeep Yadav, Erickson Paragas, Ken Korzekwa, Swati Nagar. Time-dependent enzyme inactivation: Numerical analyses of in vitro data and prediction of drug-drug interactions. Pharmacology & Therapeutics 2020, 206 , 107449.
    12. Maria Almira Correia, Paul. F. Hollenberg. Inhibition of Cytochrome P450 Enzymes. 2015, 177-259.
    13. Brooke M. Rock, Shawna M. Hengel, Dan A. Rock, Larry C. Wienkers, Kent L. Kunze. Characterization of Ritonavir-Mediated Inactivation of Cytochrome P450 3A4. Molecular Pharmacology 2014, 86 (6) , 665-674.
    14. Brooke M. VandenBrink, John A. Davis, Josh T. Pearson, Robert S. Foti, Larry C. Wienkers, Dan A. Rock. Cytochrome P450 Architecture and Cysteine Nucleophile Placement Impact Raloxifene-Mediated Mechanism-Based Inactivation. Molecular Pharmacology 2012, 82 (5) , 835-842.
    15. Kirk R. Henne, Thuy B. Tran, Brooke M. VandenBrink, Dan A. Rock, Divesh K. Aidasani, Raju Subramanian, Andrew K. Mason, David M. Stresser, Yohannes Teffera, Simon G. Wong, Michael G. Johnson, Xiaoqi Chen, George R. Tonn, Bradley K. Wong. Sequential Metabolism of AMG 487, a Novel CXCR3 Antagonist, Results in Formation of Quinone Reactive Metabolites That Covalently Modify CYP3A4 Cys239 and Cause Time-Dependent Inhibition of the Enzyme. Drug Metabolism and Disposition 2012, 40 (7) , 1429-1440.
    16. Hsia-lien Lin, Cesar Kenaan, Paul F. Hollenberg. Identification of the Residue in Human CYP3A4 That Is Covalently Modified by Bergamottin and the Reactive Intermediate That Contributes to the Grapefruit Juice Effect. Drug Metabolism and Disposition 2012, 40 (5) , 998-1006.
    17. Dan Rock, Larry C. Wienkers. Characterization of Cytochrome P 450 Mechanism‐Based Inhibition. 2010, 1-56.
    18. R. Scott Obach, Odette A. Fahmi, Robert L. Walsky. Inactivation of Human Cytochrome P450 Enzymes and Drug–Drug Interactions. 2010, 473-495.
    19. Chad L. Stoner, Michael R. Wester, Benjamin J. Burke. In Silico Approaches to Predict DDIs. 2010, 151-168.
    20. Derek C. Martyn, Joseph F. Cortese, Erin Tyndall, Justin Dick, Ralph Mazitschek, Benito Munoz, Jon Clardy. Antiplasmodial activity of piperazine sulfonamides. Bioorganic & Medicinal Chemistry Letters 2010, 20 (1) , 218-221.
    21. Ruth Hyland, R. Scott Obach, Chad Stoner, Michael West, Michael R. Wester, Kuresh Youdim, Michael Zientek. Drug–Drug Interactions: Screening for Liability and Assessment of Risk. 2009, 165-196.
    22. Dan Rock, Larry C. Wienkers. Characterization of Cytochrome P450 Mechanism‐Based Inhibition. 2009, 479-534.
    23. Sonia M. Poli. Irreversible Cytochrome P450 Inhibition: Common Substructures and Implications for Drug Development. 2008, 267-276.
    24. Shu-Feng Zhou, Charlie Changli Xue, Xue-Qing Yu, Chunguang Li, Guangji Wang. Clinically Important Drug Interactions Potentially Involving Mechanism-based Inhibition of Cytochrome P450 3A4 and the Role of Therapeutic Drug Monitoring. Therapeutic Drug Monitoring 2007, 29 (6) , 687-710.
    25. Mohamad Shebley, Paul F. Hollenberg. Mutation of a Single Residue (K262R) in P450 2B6 Leads to Loss of Mechanism-Based Inactivation by Phencyclidine. Drug Metabolism and Disposition 2007, 35 (8) , 1365-1371.
    26. Yasuhiro Masubuchi, Toshiharu Horie. Toxicological Significance of Mechanism-Based Inactivation of Cytochrome P450 Enzymes by Drugs. Critical Reviews in Toxicology 2007, 37 (5) , 389-412.
    27. Bo Wen, Jed N. Lampe, Arthur G. Roberts, William M. Atkins, A. David Rodrigues, Sidney D. Nelson. Cysteine 98 in CYP3A4 contributes to conformational integrity required for P450 interaction with CYP reductase. Archives of Biochemistry and Biophysics 2006, 454 (1) , 42-54.
    28. Ute M. Kent, Hsia-lien Lin, Kathleen R. Noon, Danni L. Harris, Paul F. Hollenberg. Metabolism of Bergamottin by Cytochromes P450 2B6 and 3A5. Journal of Pharmacology and Experimental Therapeutics 2006, 318 (3) , 992-1005.
    29. E. Row, S. A. Brown, A. V. Stachulski, M. S. Lennard. DEVELOPMENT OF NOVEL FURANOCOUMARIN DIMERS AS POTENT AND SELECTIVE INHIBITORS OF CYP3A4. Drug Metabolism and Disposition 2006, 34 (2) , 324-330.
    30. Bo Wen, Catalin E. Doneanu, Jed N. Lampe, Arthur G. Roberts, William M. Atkins, Sidney D. Nelson. Probing the CYP3A4 active site by cysteine scanning mutagenesis and photoaffinity labeling. Archives of Biochemistry and Biophysics 2005, 444 (2) , 100-111.
    31. Hsia-lien Lin, Ute M. Kent, Paul F. Hollenberg. The Grapefruit Juice Effect Is Not Limited to Cytochrome P450 (P450) 3A4: Evidence for Bergamottin-Dependent Inactivation, Heme Destruction, and Covalent Binding to Protein in P450s 2B6 and 3A5. Journal of Pharmacology and Experimental Therapeutics 2005, 313 (1) , 154-164.
    32. Petr Hodek, Lucie Bořek-Dohalská, Bruno Sopko, Miroslav Šulc, Stanislav Smrček, Jiří Hudeček, Josef Janků, Marie Stiborová. Structural requirements for inhibitors of cytochromes P450 2B: Assessment of the enzyme interaction with diamondoids. Journal of Enzyme Inhibition and Medicinal Chemistry 2005, 20 (1) , 25-33.
    33. Shufeng Zhou, Eli Chan, Wei Duan, Min Huang, Yu-Zong Chen. Drug Bioactivation Covalent Binding to Target Proteins and Toxicity Relevance. Drug Metabolism Reviews 2005, 37 (1) , 41-213.
    34. Shufeng Zhou, Sui Yung Chan, Boon Cher Goh, Eli Chan, Wei Duan, Min Huang, Howard L McLeod. Mechanism-Based Inhibition of Cytochrome P450 3A4 by Therapeutic Drugs. Clinical Pharmacokinetics 2005, 44 (3) , 279-304.
    36. Kishore K. Khan, You Qun He, Maria Almira Correia, James R. Halpert. Differential Oxidation of Mifepristone by Cytochromes P450 3A4 and 3A5: Selective Inactivation of P450 3A4. Drug Metabolism and Disposition 2002, 30 (9) , 985-990.
    37. Slobodan Rendic. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metabolism Reviews 2002, 34 (1-2) , 83-448.
    38. Maria Almira Correia, Paul R. Ortiz de Montellano. Inhibition of Cytochrome P450 Enzymes. , 247-322.

    Pair your accounts.

    Export articles to Mendeley

    Get article recommendations from ACS based on references in your Mendeley library.

    Pair your accounts.

    Export articles to Mendeley

    Get article recommendations from ACS based on references in your Mendeley library.

    You’ve supercharged your research process with ACS and Mendeley!

    STEP 1:
    Click to create an ACS ID

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    Your Mendeley pairing has expired. Please reconnect